


13 to treating withdrawal symptoms with a Ginkgo biloba extract. Claim 11 was held to be a linking claim for all 5 groups.

Applicants respectfully traverse the restriction requirement since it is believed that at most it should be a 3 way restriction and not all the claims were treated by the Examiner since no mention was made of claims 14 and 15. It is believed the Examiner is requested to reconsider the restriction requirement and group claims 4, 5 and 10 to 15 drawn to treating withdrawal symptoms with various ginkgo extracts, claims 6 to 8 drawn to treating withdrawal symptoms with tobacco or drugs inducing toxicomania. The Examiner is not correct in separating ginkgo claims as they are drawn to a single invention.

Applicants are at a loss as to how to properly respond to the restriction requirement since the Examiner did not treat claims 14 and 15 and claim 14 is the most interesting claim. Assuming the Examiner would revise the restriction as suggested by Applicants, Applicants elect without traverse claims 4, 5 and 10 to 15. If not, Applicants with a strong traverse elect whatever group the Examiner places claim 14 in since the ginkgo extracts are not patentably distinct.

Since the first office action was merely a restriction requirement, a prompt examination on the merits is requested.

Respectfully submitted,  
Hedman and Costigan


  
Charles A. Muserlian #19,683  
Attorney for Applicants  
Tel. 212 302 8989

CAM:mlp  
Enclosures

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

  
Charles A. Muserlian #19,683

  
September 5, 2006